178 related articles for article (PubMed ID: 10541835)
1. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck.
Hustinx R; Smith RJ; Benard F; Rosenthal DI; Machtay M; Farber LA; Alavi A
Eur J Nucl Med; 1999 Oct; 26(10):1345-8. PubMed ID: 10541835
[TBL] [Abstract][Full Text] [Related]
2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
3. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.
Khan N; Oriuchi N; Ninomiya H; Higuchi T; Kamada H; Endo K
Ann Nucl Med; 2004 Jul; 18(5):409-17. PubMed ID: 15462403
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
7. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
8. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules.
Matthies A; Hickeson M; Cuchiara A; Alavi A
J Nucl Med; 2002 Jul; 43(7):871-5. PubMed ID: 12097455
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
10. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.
Pauleit D; Zimmermann A; Stoffels G; Bauer D; Risse J; Flüss MO; Hamacher K; Coenen HH; Langen KJ
J Nucl Med; 2006 Feb; 47(2):256-61. PubMed ID: 16455631
[TBL] [Abstract][Full Text] [Related]
11. The effect of acquisition time on visual and semi-quantitative analysis of F-18 FDG-PET studies in patients with head and neck cancer.
Goethals I; D'Asseler Y; Dobbeleir A; Deblaere K; Ham H
Nucl Med Commun; 2010 Mar; 31(3):227-31. PubMed ID: 20023593
[TBL] [Abstract][Full Text] [Related]
12. Normal FDG distribution patterns in the head and neck: PET/CT evaluation.
Nakamoto Y; Tatsumi M; Hammoud D; Cohade C; Osman MM; Wahl RL
Radiology; 2005 Mar; 234(3):879-85. PubMed ID: 15734938
[TBL] [Abstract][Full Text] [Related]
13. Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.
Wong CY; Noujaim D; Fu HF; Huang WS; Cheng CY; Thie J; Dalal I; Chang CY; Nagle C
Mol Imaging Biol; 2009; 11(4):283-90. PubMed ID: 19326175
[TBL] [Abstract][Full Text] [Related]
14. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography.
Li P; Zhuang H; Mozley PD; Denittis A; Yeh D; Machtay M; Smith R; Alavi A
Clin Nucl Med; 2001 Feb; 26(2):131-5. PubMed ID: 11201470
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Watson NE; Randall ME; Raben M; Geisinger KR; Cappellari JO
Cancer; 1994 Aug; 74(4):1355-9. PubMed ID: 8055460
[TBL] [Abstract][Full Text] [Related]
17. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of response to radiotherapy with fluorine-18 deoxyglucose PET of head and neck squamous cell carcinomas.
Sakamoto H; Nakai Y; Ohashi Y; Matsuda M; Sakashita T; Nasako Y; Kitayama H; Kawabe J; Okamura T; Ochi H
Acta Otolaryngol Suppl; 1998; 538():254-60. PubMed ID: 9879431
[TBL] [Abstract][Full Text] [Related]
19. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
[TBL] [Abstract][Full Text] [Related]
20. Can the standardized uptake value characterize primary brain tumors on FDG-PET?
Hustinx R; Smith RJ; Benard F; Bhatnagar A; Alavi A
Eur J Nucl Med; 1999 Nov; 26(11):1501-9. PubMed ID: 10552096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
